GCP
BLPH

GSA Capital Partners’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

GSA Capital Partners’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-63,566
Closed -$330K – 1736
2021
Q1 		$330K Buy
63,566
+3,977
+7% +$27.7K 0.05% 588
2020
Q4 		$397K Buy
59,589
+31,497
+112% +$258K 0.06% 574
2020
Q3 		$286K Buy
+28,092
New +$330K 0.05% 770

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

GSA Capital Partners's BLPH Position: Q2 2021 in Review

GSA Capital Partners sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 63,566 shares — an estimated $330K sold.

GSA Capital Partners first reported a position in BLPH in Q3 2020 and held it in 3 quarters. The position peaked at $397K in Q4 2020. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • GSA Capital Partners reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • GSA Capital Partners sold 63,566 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $330K.
  • GSA Capital Partners first reported a position in Bellerophon Therapeutics, Inc. in Q3 2020 and held it in 3 quarters.
  • GSA Capital Partners's Bellerophon Therapeutics, Inc. position peaked at $397K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.